89 related articles for article (PubMed ID: 30973227)
1. Development of a NanoBRET-Based Sensitive Screening Method for CXCR4 Ligands.
Sakyiamah MM; Nomura W; Kobayakawa T; Tamamura H
Bioconjug Chem; 2019 May; 30(5):1442-1450. PubMed ID: 30973227
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.
Sakyiamah MM; Kobayakawa T; Fujino M; Konno M; Narumi T; Tanaka T; Nomura W; Yamamoto N; Murakami T; Tamamura H
Bioorg Med Chem; 2019 Mar; 27(6):1130-1138. PubMed ID: 30772128
[TBL] [Abstract][Full Text] [Related]
3. Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening.
Nomura W; Tanabe Y; Tsutsumi H; Tanaka T; Ohba K; Yamamoto N; Tamamura H
Bioconjug Chem; 2008 Sep; 19(9):1917-20. PubMed ID: 18707146
[TBL] [Abstract][Full Text] [Related]
4. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Environment-Sensitive Fluorescent Ligands of β-Adrenergic Receptors for Cell Imaging and NanoBRET Assay.
Li W; Ma Z; Chen J; Dong G; Du L; Li M
Anal Chem; 2022 May; 94(19):7021-7028. PubMed ID: 35504022
[TBL] [Abstract][Full Text] [Related]
6. New Horizons on Molecular Pharmacology Applied to Drug Discovery: When Resonance Overcomes Radioligand Binding.
Pernomian L; Gomes MS; Moreira JD; da Silva CHTP; Rosa JMC; Cardoso CRB
Curr Radiopharm; 2017; 10(1):16-20. PubMed ID: 28183248
[TBL] [Abstract][Full Text] [Related]
7. The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Di Salvo J; Koch GE; Johnson KE; Blake AD; Daugherty BL; DeMartino JA; Sirotina-Meisher A; Liu Y; Springer MS; Cascieri MA; Sullivan KA
Eur J Pharmacol; 2000 Dec; 409(2):143-54. PubMed ID: 11104827
[TBL] [Abstract][Full Text] [Related]
8. A novel CXCR4-selective high-affinity fluorescent probe and its application in competitive binding assays.
Yang Y; Zhang Q; Gao M; Yang X; Huang Z; An J
Biochemistry; 2014 Aug; 53(30):4881-3. PubMed ID: 25058910
[TBL] [Abstract][Full Text] [Related]
9. Development and application of fluorescent SDF-1 derivatives.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Kodama E; Matsuoka M; Fujii N
Future Med Chem; 2012 May; 4(7):837-44. PubMed ID: 22571609
[TBL] [Abstract][Full Text] [Related]
10. Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.
Harms M; Gilg A; Ständker L; Beer AJ; Mayer B; Rasche V; Gruber CW; Münch J
Sci Rep; 2020 Sep; 10(1):16036. PubMed ID: 32994431
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.
Castaldo C; Benicchi T; Otrocka M; Mori E; Pilli E; Ferruzzi P; Valensin S; Diamanti D; Fecke W; Varrone M; Porcari V
J Biomol Screen; 2014 Jul; 19(6):859-69. PubMed ID: 24632660
[TBL] [Abstract][Full Text] [Related]
12. Peptide-functionalized luminescent iridium complexes for lifetime imaging of CXCR4 expression.
Kuil J; Steunenberg P; Chin PT; Oldenburg J; Jalink K; Velders AH; van Leeuwen FW
Chembiochem; 2011 Aug; 12(12):1897-903. PubMed ID: 21739561
[TBL] [Abstract][Full Text] [Related]
13. Regulation of CXCR4 receptor dimerization by the chemokine SDF-1alpha and the HIV-1 coat protein gp120: a fluorescence resonance energy transfer (FRET) study.
Toth PT; Ren D; Miller RJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):8-17. PubMed ID: 15014135
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study on artificial CXCR4 ligands possessing the cyclic pentapeptide scaffold: the exploration of amino acid residues of pentapeptides by substitutions of several aromatic amino acids.
Tanaka T; Nomura W; Narumi T; Esaka A; Oishi S; Ohashi N; Itotani K; Evans BJ; Wang ZX; Peiper SC; Fujii N; Tamamura H
Org Biomol Chem; 2009 Sep; 7(18):3805-9. PubMed ID: 19707686
[TBL] [Abstract][Full Text] [Related]
15. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
16. NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.
White CW; Johnstone EKM; See HB; Pfleger KDG
Cell Signal; 2019 Feb; 54():27-34. PubMed ID: 30471466
[TBL] [Abstract][Full Text] [Related]
17. Measuring Protein-Protein Interactions in Cells using Nanoluciferase Bioluminescence Resonance Energy Transfer (NanoBRET) Assay.
Szewczyk MM; Owens DDG; Barsyte-Lovejoy D
Methods Mol Biol; 2023; 2706():137-148. PubMed ID: 37558946
[TBL] [Abstract][Full Text] [Related]
18. Development of a receptor-targeted gene delivery system using CXCR4 ligand-conjugated cross-linking peptides.
Egorova A; Bogacheva M; Shubina A; Baranov V; Kiselev A
J Gene Med; 2014; 16(11-12):336-51. PubMed ID: 25382058
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
20. Use of a new proximity assay (NanoBRET) to investigate the ligand-binding characteristics of three fluorescent ligands to the human
Soave M; Stoddart LA; Brown A; Woolard J; Hill SJ
Pharmacol Res Perspect; 2016 Oct; 4(5):e00250. PubMed ID: 27588207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
